You just read:

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

News provided by

Polaris Group

Dec 03, 2014, 01:30 ET